Katharina Ribbeck is a German-American biologist. She is the Andrew (1956) and Erna Viterbi Professor of Biological Engineering at the Massachusetts Institute of Technology. Known as one of the first researchers to study how mucus impacts microbial behavior, Ribbeck investigates both the function of mucus as a barrier to pathogens such as fungi, bacteria, and viruses and how mucus can be leveraged for therapeutic purposes without promoting antimicrobial resistance. She has also studied changes that cervical mucus undergoes before birth, informing potential diagnostic tools for assessing the risk of preterm birth. Building on this work, Ribbeck co-founded Tulip Biosciences, a platform company focused on the development of mucus-inspired biomaterials to support healthy functioning of the mucus barrier.
Education Ribbeck received her B.S. in biology from the University of Heidelberg in 1998. During her senior year, she attended the University of California, San Diego, to study neurobiology for her diploma thesis. She earned her Ph.D. in biology, also from the University of Heidelberg, in 2001.
Career Upon completing her Ph.D., Ribbeck continued her research as a postdoctoral scientist at the European Molecular Biology Laboratory in Heidelberg, Germany, and then Harvard Medical School. After her postdoctoral research, she moved to Harvard University as an independent Bauer Fellow in 2007, where she began to investigate how particles and bacteria move through mucus barriers. In 2010, Ribbeck moved to the Department of Biological Engineering at the Massachusetts Institute of Technology as an assistant professor. She attained tenure as a full professor in 2017. In 2025, Ribbeck co-founded Tulip Biosciences, a biotechnology research company that develops and produces mucin-mimetic biomaterials to restore the natural mucus barrier, focusing on vaginal health and antibiotic resistance.
Research on nuclear pore complexes During her Ph.D. work, Ribbeck investigated the selective transport of molecules through the nuclear pore complex, which is partly mediated by a hydrogel barrier. With her Ph.D. advisor, Dirk Görlich, Ribbeck developed a selective phase model for molecular transport through the nuclear pore barrier. Görlich and Ribbeck also showed that molecular transport through nuclear pore complexes may be facilitated by hydrophobic interactions.
Research on mitotic spindles As a postdoctoral researcher at the European Molecular Biology Laboratory, Ribbeck studied proteins involved in the organization of the mitotic spindle, a dynamic bundle consisting of proteins and molecules that aids in chromosome segregation during cell division. Her research contributed to the discovery of a novel protein (NuSAP) that plays a crucial role in mitotic spindle organization.
Research on functions of mucus In 2007, Ribbeck's research returned to hydrogels, with a specific focus on mucus, i.e., a large natural hydrogel that is closely related to the polymer network she and Görlich had proposed to exist within nuclear pore complexes. Her work has elucidated the role of mucins, a primary component of mucus, in human health. Ribbeck is known for her pioneering work in this field, which has shown that mucus plays an active role in protecting against harmful pathogens, including fungi, bacteria, and viruses. Specifically, her research has shown that mucins and their associated sugar chains (glycans) can "tame" pathogens by inhibiting virulence traits such as biofilm formation, cell adhesion, and toxin secretion, without inducing antimicrobial resistance. She has shown that mucins prevent bacteria such as Pseudomonas aeruginosa and Streptococcus mutans, the bacteria that cause tooth decay, from forming biofilms, which make them difficult to eradicate. Ribbeck demonstrated that mucin glycans can reduce the virulence of pathogens such as Pseudomonas aeruginosa, a bacterium that can cause illness in individuals with cystic fibrosis or compromised immune systems, and Streptococcus pneumoniae, a pathogen that causes pneumonia and meningitis, by inhibiting the cell-cell communication, toxin secretion, and biofilm formation ability of these bacteria. Ribbeck's work has also demonstrated the role of mucus in protecting against fungal infections. Her studies have shown that mucins and specific mucin glycans induce a morphological change, accompanied by a reduction in biofilm formation and cell adhesion, in Candida albicans, a fungal pathogen that causes a variety of diseases in humans. Her work has also shown that mucins found in multiple types of mucus, including human spit, can prevent fungal pathogens from causing disease in healthy humans. Ribbeck identified a correlation between the properties of mucus in the cervix in pregnant women and the likelihood of preterm birth and has developed probes to test mucus permeability as a step towards diagnosing the risk for premature birth. Ribbeck has extensively investigated the biophysical properties of mucus and other hydrogels and the mechanisms by which some particles and molecules, including viruses such as SARS-CoV-2, selectively pass through the barrier. Ribbeck has also studied hydrogels produced by pathogens and has found that the extracellular matrix formed by the pathogenic bacterium Pseudomonas aeruginosa protects the bacterium against antibiotics.
… excerpt ends here. Continue reading the full article.
